Antiobesity medications
Antiobesity medications has been studied in 5 papers since 2024: 1 observational study in people, 4 reviews; 1 in the past year. The newest paper, Mar 10, 2026: “Weight loss as the optimal cardiometabolic management strategy for preventing and treating heart failure”.
5 papers study it7 findingsUpdated
“Patients receiving AOMs showed an 8% risk reduction in any CVD.”
None of its findings points the other way.
- 2 independent labs in 1 country
- Funders: National Institute of Diabetes and Digestive and Kidney Diseases and 4 more
- 1 of 5 findings with company ties
- Humans1
What did studies of Antiobesity medications find?
2Studies of Antiobesity medications measured 2 outcomes; the most studied are hypertension (1 study) and body weight (1).
Hypertension
downin humans1
1 study
Hypertension
downin humans1
Antiobesity medications decrease hypertension in humans.
“AOMs can improve cardiovascular outcomes, hypertension, hyperlipidemia, metabolic liver disease, obstructive sleep apnea, and chronic kidney disease.”
Review
Antiobesity Medications for Older Adults-the New, the Good, the Bad, and the Unknown
Obesity (Silver Spring, Md.)
Body weight
downin humans1
1 study
Body weight
downin humans1
Antiobesity medications decrease body weight in humans.
“All studies found statistically significant weight reduction between intervention and placebo groups or compared with baseline weight.”
Reviewobesity
Efficacy of antiobesity medications for weight reduction in older adults: a systematic review
Obesity (Silver Spring, Md.)
What is Antiobesity medications linked with?
5Studies link Antiobesity medications with 5 measures, most often sarcopenia (1 study), arrhythmia (1) and atrial fibrillation (1).
Sarcopenia
upin humans1
1 study
Sarcopenia
upin humans1
Antiobesity medications raise the risk of sarcopenia in humans.
“Weight loss in older adults using AOMs is associated with an increased risk of sarcopenia.”
Review
Antiobesity Medications for Older Adults-the New, the Good, the Bad, and the Unknown
Obesity (Silver Spring, Md.)
Arrhythmia
downin humans1
1 study
Arrhythmia
downin humans1
Antiobesity medications lower the risk of arrhythmia in humans (3.59% vs. 4.14%, p < 0.0153).
“arrhythmia (3.59% vs. 4.14%, p < 0.0153)”
Humansobesity
The association between weight loss medications and cardiovascular complications
Obesity (Silver Spring, Md.)
Atrial fibrillation
downin humans1
1 study
Atrial fibrillation
downin humans1
Antiobesity medications lower the risk of atrial fibrillation in humans (3.83% vs. 5.17%, p < 0.0001).
“atrial fibrillation (3.83% vs. 5.17%, p < 0.0001)”
Humansobesity
The association between weight loss medications and cardiovascular complications
Obesity (Silver Spring, Md.)
Heart failure
downin humans1
1 study
Heart failure
downin humans1
Antiobesity medications lower the risk of heart failure in humans (4.89% vs. 6.13%, p < 0.0001).
“For patients with AOMs, less incidence of heart failure (4.89% vs. 6.13%, p < 0.0001)”
Humansobesity
The association between weight loss medications and cardiovascular complications
Obesity (Silver Spring, Md.)
Cardiovascular disease
downin humans1−8% risk reduction
1 study
Cardiovascular disease
downin humans1−8% risk reduction
Antiobesity medications lower the risk of cardiovascular disease in humans (8% risk reduction).
“Patients receiving AOMs showed an 8% risk reduction in any CVD.”
Humansobesityfirst 375 days
The association between weight loss medications and cardiovascular complications
Obesity (Silver Spring, Md.)